Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD01005 ...
Drug Name Hydroxyurea
Molecular Weight 76.0547
Molecular Formula CH4N2O2
CAS Number 127-07-1
SMILES NC(=O)NO
External Links
DRUGBANK DB01005
T3DB T3D4767
PubChem Compound 3657
PDR 888
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P -1.8 - -1.8 - HANSCH,C ET AL. (1995)
Melting Point 134.5 ℃ 133-136 ℃ U.S. Patent 2,705,727.
Water Solubility 1000000.0 mg/L 1000000 mg/L MERCK INDEX 1996)
Log S 1.12 - 1.12 - ADME Research, USCD

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Reference
Bioavailability 108.0 % 108±18 % PO, oral; solid tumors; The Pharmacological Basis of Therapeutics
Bioavailability 93.5 % 79-108 % PO, oral; solid tumors; The Pharmacological Basis of Therapeutics
C Max 76587082.9 ng/ml 1007±371 mM intravenous injection, IV; solid tumors; The Pharmacological Basis of Therapeutics
C Max 60387431.8 ng/ml 794±241 mM PO, oral; solid tumors; The Pharmacological Basis of Therapeutics
T Max 0.50 h 0.5 h intravenous injection, IV; solid tumors; The Pharmacological Basis of Therapeutics
T Max 1.2 h 1.2±1.2 h PO, oral; solid tumors; The Pharmacological Basis of Therapeutics
Clearance 3.3 L/h/m2 36.2-72.3 ml/min/m2 The Pharmacological Basis of Therapeutics
Clearance 0.0900 L/h/kg 1.5 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 19.7 L/m2 19.7±4.6 L/m2 The Pharmacological Basis of Therapeutics
Volume of Distribution 0.52 L/kg 0.52 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 3.5 h 3-4 h DRUGBANK
Half-life 3.4 h 3.4±0.7(2.8-4.5) h Male, men;  Female, women; solid tumors; patients; The Pharmacological Basis of Therapeutics
Half-life 3.4 h 3.4 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 7330.0 mg/kg 7330.0 mg/kg PO, oral; mouse; DRUGBANK
Toxicity LD50 5760.0 mg/kg 5760.0 mg/kg PO, oral; Rattus, Rat; DRUGBANK
Toxicity LD50 7330.0 mg/kg 7330.0 mg/kg PO, oral; mouse; T3DB
Toxicity LD50 5760.0 mg/kg 5760.0 mg/kg PO, oral; Rattus, Rat; T3DB
Eliminate Route 35.8 % 35.8±14.2 % Urinary excretion; solid tumors; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 0 % ~0 % solid tumors; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 35.0 mg/kg/day 35 mg/kg/day PO, oral Hydrea hydroxyurea PDR
Max dose for children 3000.0 mg/m2 3000 mg/m2 PO, oral Hydrea hydroxyurea PDR
Max dose for children 3000.0 mg/m2 3000 mg/m2 PO, oral Hydrea hydroxyurea PDR
Max dose for adolescents 35.0 mg/kg/day 35 mg/kg/day PO, oral Hydrea hydroxyurea PDR
Max dose for adolescents 3000.0 mg/m2 3000 mg/m2 PO, oral Hydrea hydroxyurea PDR
Max dose for adults 80.0 mg/day 80 mg/day PO, oral Hydrea hydroxyurea PDR
Max dose for geriatric 80.0 mg/kg 80 mg/kg PO, oral Hydrea hydroxyurea PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1